B-lymphoblastic lymphoma (B-LBL) is a fast-growing type of non-Hodgkin lymphoma that starts from immature B cells, a type of white blood cell that normally helps the body fight infection. It is closely related to B-cell acute lymphoblastic leukemia (B-ALL). The two conditions consist of the same type of cancer cell and differ mainly in where the cancer is found. In B-LBL, the cancer cells grow mainly as masses in lymph nodes or other tissues outside the bone marrow. In B-ALL, the same cells fill the bone marrow and often spill into the blood.
B-LBL can affect people of any age but is most common in children and young adults. Because it grows quickly, it is usually treated promptly with intensive chemotherapy. This article will help you understand the findings in your pathology report for B-lymphoblastic lymphoma, what each term means, and why it matters for your care or the care of your child.
The exact cause of B-lymphoblastic lymphoma (B-LBL) is usually not known. The disease begins when genetic changes (mutations) accumulate in an immature B cell, allowing it to grow out of control and evade the normal signals that tell a cell to die. A few factors may increase the risk:
The symptoms of B-lymphoblastic lymphoma (B-LBL) depend on where the masses develop and how far the disease has spread, so they vary widely from one person to another. Common symptoms include:
The diagnosis of B-lymphoblastic lymphoma (B-LBL) is made by examining a tumor sample under the microscope. A biopsy is taken from an enlarged lymph node or mass and sent to a pathologist, a doctor who examines tissues under the microscope. The pathologist confirms that the tumor is made up of immature lymphoid cells (lymphoblasts) and rules out other types of lymphoma and leukemia.
Several laboratory tests are used together to confirm the diagnosis. Immunohistochemistry and flow cytometry use antibodies to detect proteins on and inside the cells. In B-LBL, the cells express B-cell markers such as CD19, CD22, and CD79a, along with immaturity markers such as TdT and CD34, whereas CD20 is often weak or absent. These results confirm that the cells are immature B cells. Chromosome and molecular tests look for the genetic changes described later in this article.
A bone marrow biopsy is also performed to check whether the bone marrow contains cancer cells. This helps distinguish B-LBL, in which the disease is mainly outside the marrow, from B-ALL, in which it is mainly in the marrow. A sample of the fluid around the brain and spinal cord (cerebrospinal fluid) is usually collected via lumbar puncture to assess for spread to the central nervous system. Imaging tests such as CT and PET scans are used to map where the disease is located and how far it has spread, which is important for staging.
Under the microscope, B-lymphoblastic lymphoma (B-LBL) consists of lymphoblasts, immature B cells that are medium to large in size. Typical features include:
B-lymphoblastic lymphoma (B-LBL) is classified into subtypes based on genetic changes in lymphoblasts, using the same system as for B-ALL. Pathologists look for these changes using tests such as FISH (fluorescence in situ hybridization), PCR (polymerase chain reaction), and next-generation sequencing (NGS), which can detect gene fusions and chromosomal copy-number changes. These changes are among the most important findings in the report because they guide treatment and help predict how the lymphoma will behave. Common patterns include:
Your report will describe any genetic changes that were found and may list the World Health Organization (WHO) subtype based on those changes.
After treatment for B-lymphoblastic lymphoma (B-LBL) begins, very sensitive tests such as flow cytometry, PCR, or NGS are used to look for tiny numbers of cancer cells that may remain, sometimes as few as one cancer cell among a million normal cells. This is called measurable residual disease, also called minimal residual disease (MRD). The MRD result is one of the most sensitive measures of how well treatment is working and of the risk that the lymphoma will return. Patients with no detectable MRD after therapy generally have a more favorable outlook.
Because B-lymphoblastic lymphoma (B-LBL) forms masses, it is staged to describe how far the disease has spread. This is different from B-ALL, which begins throughout the bone marrow and is not staged. Staging uses a lymphoma system rather than the size-based system used for solid tumors. In children and teenagers, the International Pediatric Non-Hodgkin Lymphoma Staging System (or the older St. Jude/Murphy system) is used; in adults, the Lugano (Ann Arbor) system is used. These systems divide the disease into four stages based on how many areas of the body are involved and whether the bone marrow or central nervous system is affected.
Because B-LBL is treated with the same intensive chemotherapy used for B-ALL, the genetic findings and the response to treatment (including MRD) carry significant weight when the care team plans treatment, alongside the stage.
Prognosis means the expected outcome of a disease. The outlook for B-lymphoblastic lymphoma (B-LBL) depends on a combination of factors, including the patient’s age, whether the bone marrow or central nervous system is involved, the genetic changes in the cancer cells, and the treatment response, as measured by MRD. Children with B-LBL generally have an excellent prognosis, with complete remission rates above 95%. Adults have somewhat lower remission rates, ranging from about 60 to 85%, and outcomes vary depending on genetic findings and the disease’s response to therapy. Your prognosis depends on your own combination of these factors, which your care team can explain in the context of your specific report.
Once B-lymphoblastic lymphoma (B-LBL) is confirmed, the care team plans treatment based on the genetic changes found, the patient’s age, the stage, and the overall risk. B-LBL is treated with the same intensive regimens used for B-ALL, usually over about two to three years, delivered in phases. The findings on the pathology report shape several decisions:
Throughout treatment, blood counts, repeat bone marrow biopsies, and MRD testing are used to assess lymphoma response, and the results guide decisions about whether more therapy is needed. Care is provided by a team that usually includes a hematologist or oncologist, specialized nurses, and supportive care specialists, and clinical trials are often available. Decisions about which of these approaches apply are made by the treatment team together with the patient or family, based on the specific findings in the report.